Logo image of OCUL

OCULAR THERAPEUTIX INC (OCUL) Stock Fundamental Analysis

NASDAQ:OCUL - Nasdaq - US67576A1007 - Common Stock - Currency: USD

11.03  -0.05 (-0.45%)

After market: 11.03 0 (0%)

Fundamental Rating

4

Taking everything into account, OCUL scores 4 out of 10 in our fundamental rating. OCUL was compared to 194 industry peers in the Pharmaceuticals industry. The financial health of OCUL is average, but there are quite some concerns on its profitability. While showing a medium growth rate, OCUL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

OCUL had negative earnings in the past year.
In the past year OCUL has reported a negative cash flow from operations.
OCUL had negative earnings in each of the past 5 years.
OCUL had a negative operating cash flow in each of the past 5 years.
OCUL Yearly Net Income VS EBIT VS OCF VS FCFOCUL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

OCUL has a Return On Assets (-47.48%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -72.47%, OCUL is in line with its industry, outperforming 45.36% of the companies in the same industry.
Industry RankSector Rank
ROA -47.48%
ROE -72.47%
ROIC N/A
ROA(3y)-40.62%
ROA(5y)-36.9%
ROE(3y)-116.88%
ROE(5y)-112.52%
ROIC(3y)N/A
ROIC(5y)N/A
OCUL Yearly ROA, ROE, ROICOCUL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K 2K

1.3 Margins

OCUL's Gross Margin of 90.67% is amongst the best of the industry. OCUL outperforms 94.33% of its industry peers.
OCUL's Gross Margin has improved in the last couple of years.
OCUL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.47%
GM growth 5Y15.21%
OCUL Yearly Profit, Operating, Gross MarginsOCUL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

6

2. Health

2.1 Basic Checks

OCUL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OCUL has been increased compared to 1 year ago.
OCUL has more shares outstanding than it did 5 years ago.
OCUL has a better debt/assets ratio than last year.
OCUL Yearly Shares OutstandingOCUL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
OCUL Yearly Total Debt VS Total AssetsOCUL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

OCUL has an Altman-Z score of 3.76. This indicates that OCUL is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.76, OCUL is in the better half of the industry, outperforming 76.29% of the companies in the same industry.
OCUL has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
OCUL has a Debt to Equity ratio (0.26) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Altman-Z 3.76
ROIC/WACCN/A
WACC10.62%
OCUL Yearly LT Debt VS Equity VS FCFOCUL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

OCUL has a Current Ratio of 10.22. This indicates that OCUL is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 10.22, OCUL belongs to the best of the industry, outperforming 82.99% of the companies in the same industry.
A Quick Ratio of 10.14 indicates that OCUL has no problem at all paying its short term obligations.
The Quick ratio of OCUL (10.14) is better than 82.99% of its industry peers.
Industry RankSector Rank
Current Ratio 10.22
Quick Ratio 10.14
OCUL Yearly Current Assets VS Current LiabilitesOCUL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.30% over the past year.
OCUL shows a decrease in Revenue. In the last year, the revenue decreased by -0.33%.
OCUL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 72.02% yearly.
EPS 1Y (TTM)22.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.71%
Revenue 1Y (TTM)-0.33%
Revenue growth 3Y13.55%
Revenue growth 5Y72.02%
Sales Q2Q%-27.59%

3.2 Future

The Earnings Per Share is expected to grow by 20.93% on average over the next years. This is a very strong growth
OCUL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 58.03% yearly.
EPS Next Y0.45%
EPS Next 2Y1.88%
EPS Next 3Y8.03%
EPS Next 5Y20.93%
Revenue Next Year-13.72%
Revenue Next 2Y2.11%
Revenue Next 3Y23.51%
Revenue Next 5Y58.03%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
OCUL Yearly Revenue VS EstimatesOCUL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B
OCUL Yearly EPS VS EstimatesOCUL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OCUL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OCUL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OCUL Price Earnings VS Forward Price EarningsOCUL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OCUL Per share dataOCUL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.88%
EPS Next 3Y8.03%

More info and screens

0

5. Dividend

5.1 Amount

OCUL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OCULAR THERAPEUTIX INC

NASDAQ:OCUL (7/11/2025, 8:00:02 PM)

After market: 11.03 0 (0%)

11.03

-0.05 (-0.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-05 2025-05-05/bmo
Earnings (Next)08-04 2025-08-04/amc
Inst Owners85.54%
Inst Owner Change0%
Ins Owners3.02%
Ins Owner Change24.17%
Market Cap1.76B
Analysts86.67
Price Target17.8 (61.38%)
Short Float %9.55%
Short Ratio6.71
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-19.8%
Min EPS beat(2)-26.63%
Max EPS beat(2)-12.97%
EPS beat(4)1
Avg EPS beat(4)-10.94%
Min EPS beat(4)-26.63%
Max EPS beat(4)10.95%
EPS beat(8)3
Avg EPS beat(8)-32.19%
EPS beat(12)4
Avg EPS beat(12)-27.48%
EPS beat(16)8
Avg EPS beat(16)-3.13%
Revenue beat(2)0
Avg Revenue beat(2)-20.17%
Min Revenue beat(2)-37.69%
Max Revenue beat(2)-2.66%
Revenue beat(4)1
Avg Revenue beat(4)-12.56%
Min Revenue beat(4)-37.69%
Max Revenue beat(4)1.86%
Revenue beat(8)2
Avg Revenue beat(8)-8.17%
Revenue beat(12)3
Avg Revenue beat(12)-8.64%
Revenue beat(16)4
Avg Revenue beat(16)-7.95%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-1.19%
EPS NQ rev (3m)-19.83%
EPS NY rev (1m)-0.59%
EPS NY rev (3m)-18.25%
Revenue NQ rev (1m)-2.51%
Revenue NQ rev (3m)-24.82%
Revenue NY rev (1m)-1.97%
Revenue NY rev (3m)-22.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 29.46
P/FCF N/A
P/OCF N/A
P/B 6.61
P/tB 6.61
EV/EBITDA N/A
EPS(TTM)-1.15
EYN/A
EPS(NY)-1.41
Fwd EYN/A
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.91
OCFYN/A
SpS0.37
BVpS1.67
TBVpS1.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.48%
ROE -72.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.68%
FCFM N/A
ROA(3y)-40.62%
ROA(5y)-36.9%
ROE(3y)-116.88%
ROE(5y)-112.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.47%
GM growth 5Y15.21%
F-Score2
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 77.1%
Cap/Sales 4.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.22
Quick Ratio 10.14
Altman-Z 3.76
F-Score2
WACC10.62%
ROIC/WACCN/A
Cap/Depr(3y)138.13%
Cap/Depr(5y)98.78%
Cap/Sales(3y)6.55%
Cap/Sales(5y)5.44%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.71%
EPS Next Y0.45%
EPS Next 2Y1.88%
EPS Next 3Y8.03%
EPS Next 5Y20.93%
Revenue 1Y (TTM)-0.33%
Revenue growth 3Y13.55%
Revenue growth 5Y72.02%
Sales Q2Q%-27.59%
Revenue Next Year-13.72%
Revenue Next 2Y2.11%
Revenue Next 3Y23.51%
Revenue Next 5Y58.03%
EBIT growth 1Y-123.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.35%
EBIT Next 3Y0.4%
EBIT Next 5Y25.31%
FCF growth 1Y-118.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-138.58%
OCF growth 3YN/A
OCF growth 5YN/A